Roucou, Xavier

Directeur de département, Faculté de médecine et des sciences de la santé
FMSS Dép. de biochimie et de génomique fonction.

Coordonnées

Courriel


819-821-8000, poste 72240


Site Web

Diplômes

(2004) Post-doctorate (Postdoctorate Neurosciences). McGill University.

(2002) Post-doctorate (Postdoctorate Cell Biology). University of Geneva.

(2000) Post-doctorate (Postdoctorate Biochemistry and Molecular Biology). Monash University.

(1996) Doctorate (Doctorate Life Sciences). Université Victor Ségalen Bordeaux 2.

(1992) Master's non-Thesis (Master's Biological Sciences - Masters). Université Victor Ségalen Bordeaux 2.

Présentation

Sujets de recherche

Apoptosis, Cell, Cellular Degeneration, Enzymes and Proteins, Neurodegenerative Diseases, Nucleic Acids.

Disciplines de recherche

Biochemistry, Cell Biology, Molecular Biology.

Mots-clés

Membranes Biochemistry, Mitochondria/Apoptosis, Protein database, Proteomics, Site-directed Mutagenesis.

Intérêts de recherche

Functional proteomics and discovery of novel proteins Pathobiological function of proteins in neuronal degeneration and cancer

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français, Espagnol (castillan)

Prix et distinctions

  • (2022) Canada Research Chair Tier1 in Functional Proteomics and Discovery of Novel Proteins. Canadian Institutes of Health Research. (Distinction).
  • (2019) OpenProt: a more comprehensive guide to explore eukaryotic coding potential and proteomes., Nucleic Acids Research, 2019 (doi: 10.1093/nar/gky936), has been recommended in F1000Prime as being of special significance in its field. F1000Prime.
  • (2014) Prix Jean de Margerie pour la publication de l'année en sciences biomédicales. Université de Sherbrooke. (Distinction).
  • (2014) Prix d'excellence, créativité et innovation du CHUS. Centre Hospitalier Univ. de Sherbrooke. (Distinction).
  • (2014) Prix de la recherche et de la création de l'Université de Sherbrooke. Université de Sherbrooke. (Prize / Award).
  • (2014) Canadian researcher of the month, March 2014. Canadians for Health Research. (Distinction).
  • (2014) Découverte de l'année par le magazine Québec Science (2013). Quebec Science Magazine. (Distinction).

Financement

Grant. (Awarded). Co-applicant. UbiquitinKEKS: function of a novel ubiquitin isoform encoded by UBBP4. Canadian Institutes of Health Research (CIHR). Project. 891226 $ (2018-2023).

Research Chair. (Awarded). Principal Applicant. Canada Research Chair in Functional Proteomics and Discovery of Novel Proteins. Canadian Institutes of Health Research (CIHR). Canada Research Chair Tier1. 1400000 $ (2015-2022).

(Awarded). Co-investigator. Development of precision therapeutic vaccines against acute myeloid and lymphoid leukemias. Fonds de recherche du Québec - Santé (FRQS). Oncopole. 1500000 $ (2018-2021).

Grant. (Awarded). Principal Investigator. Cracking the FUS code in ALS: From the dual-coding gene FUS, alt-FUS engages too in the pathology. Amyotrophic Lateral Sclerosis (ALS) Society of Canada. Operating. 125000 $ (2018-2020).

(Under Review). Principal Applicant. OpenProt. Compute Canada. Fast Track. 190000 $ (2019-2020).

(Awarded). Principal Applicant. OpenProt. Compute Canada. Fast Track (1138 CPU). 179983 $ (2018-2019).

Grant. (Awarded). Co-applicant. Precision medicine: a mass spectrometer for the discovery of new protein biomarkers. Canada Foundation for Innovation (CFI). John R. Evans Leaders Fund. 1583499 $ (2018-2019).

(Completed). Principal Applicant. OpenProt. Compute Canada. Resources for Research Groups (1224 CPU). 231140 $ (2017-2018).

(Completed). Principal Applicant. OpenProt. Compute Canada. Resources for Research Groups (1181 CPU). 195260 $ (2016-2017).

Grant. (Completed). Co-applicant. 600 MHz Solution-State NMR Upgrade for Structural Biology. Canada Foundation for Innovation (CFI). John R. Evans Leaders Fund. 891938 $ (2016).

Publications

Articles de revue

  • Brunet MA*, Brunelle M, Lucier JF, Delcourt V*, Levesque M, Grenier F, Samandi S*, Leblanc S*, Aguilar JD, Dufour P, Jacques JF, Fournier I, Ouangraoua A, Scott MS, Boisvert FM, Roucou X. (2018). OpenProt: a more comprehensive guideto explore eukaryotic coding potential and proteomes. Nucleic Acids Research, 47(D1), D403-D410. DOI. (Published).
  • Brunet MA*, Levesque SA, Hunting DJ, Cohen AA, Roucou X. (2018). Recognition of the polycistronicnature of human genes is critical to understanding the genotype-phenotyperelationship. Genome Research, 28(5), 609-624. DOI. (Published).
  • Delcourt V*, Staskevicius A*, Salzet M, Fournier I, Roucou X. (2018). Small proteins encoded by unannotated ORFs are rising stars of the proteome, confirming shortcomings in genome annotations and current vision of an mRNA. Proteomics, 18(10), Not yet known. (Published).
  • Delcourt V*, Franck J, Quanico J, Gimeno JP, Wisztorski M, Raffo-Romero A, Kobeissy F, Roucou X, Salzet M, Fournier I. (2018). Spatially-Resolved Top-down Proteomics Bridged to MALDI MS Imaging Reveals the Molecular Physiome of Brain Regions. Molecular and Cellular Proteomics, 17(2), 357-372. (Published).
  • Delcourt V*, Brunelle M, Roy AV*, Jacques JF, Salzet M, Fournier I, Roucou X. (2018). The protein coded by a short open reading frame, not by the annotated coding sequence is the main gene product of the dual-coding gene MIEF1. Molecular and Cellular Proteomics, 17(12), 2402-2411. DOI. (Published).
  • Delcourt V*, Franck J, Leblanc E, Narducci F, Robin YM, Gimeno JP, Quanico J, Wisztorski M, Kobeissy F, Jacques JF, Roucou X, Salzet M, Fournier I. (2017). Combined Mass SpectrometryImaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome inOvarian Cancer. EBioMedicine, 21, 55-64. DOI. (Published).
  • Samandi S*, Roy AV*, Delcourt V*, Lucier JF, Gagnon J, Beaudoin MC*, Vanderperre B*, Breton MA*, Motard J, Jacques JF, Brunelle M, Gagnon-Arsenault I, Fournier I, Ouangraoua A, Hunting DJ, Cohen AA, Landry CR, Scott MS, Roucou X. (2017). Deep transcriptome annotation enables the discovery and functional characterizationof cryptic small proteins. eLife, 6:e27860, 1-32. DOI. (Published).
  • Delcourt V*, Franck J, Quanico J, Gimeno JP, Wisztorski M, Raffo Romero A, Kobeissy F, Roucou X, Salzet M, Fournier I. (2017). Top-down microproteomics bridgedto MALDI MS imaging reveals the molecular physiome of brain regions. Molecular & cellular proteomics, Not yet available, Not yet available. DOI. (Published).
  • Mouilleron H*, Delcourt V*, Roucou X. (2016). Death of a dogma: eukaryotic mRNAs can code for more than one protein. Nucleic Acids Research, 44(1), 14-23. (Published).
  • Landry CR, Zhonga X*, Nielly-Thibault L*, Roucou X*. (2015). Found in translation: Function and evolution of a recently discovered proteome. Current Opinion in Structural Biology, 32, 74-81. (Published).
  • Béland M*, Bédard M*, Tremblay G, Lavigne P, Roucou X. (2014). Aβ induces its ownprion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphousaggregates. Neurobiol Aging, 35(7), 1537-1548. (Published).
  • Roucou X. (2014). Regulation of PrP(C) signaling and processing by dimerization. Front Cell Dev Biol, 2(57), 1-6. (Published).
  • Béland M*, Roucou X. (2014). Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases. Prion, 8(1), 106-110. (Published).
  • Bergeron D*, Lapointe C*, Bissonnette C*, Tremblay G, Motard J, Roucou X. (2013). An out-of-frame overlapping reading frame in the ataxin-1 coding sequence encodes a novel ataxin-1 interacting protein. J Biol Chem, 288(30), 21824-21835. (Published).
  • Vanderperre B*, Lucier JF, Bissonnette C*, Motard J, Tremblay G, Vanderperre S*, Wisztorski M, Salzet M, Boisvert FM, Roucou X. (2013). Direct detection of alternative open reading framestranslation products in human significantly expands the proteome. PLoS One, 8(8), e70698. (Published).
  • Béland M*, Roucou X. (2013). Homodimerization as a molecular switch between low and high efficiency PrP (C) cell surface delivery and neuroprotective activity. Prion, 7(2), 170-174. (Published).
  • Forget KJ*, Tremblay G, Roucou X. (2013). p53Aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLoS One, 8(7), e69242. (Published).
  • Béland M*, Roucou X. (2012). The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions. Journal of neurochemistry, 120(6), 853-868. (Published).
  • Roostaee A (student I supervised), Roostaee M, Roucou X. (2010). An Update on Prion Biology and Proteomics. Current Proteomics, 7(1), 36-48. (Published).

Chapitres de livre

  • Maxime Béland, Xavier Roucou. (2014). Utiliser la protéine prion contre les espèces toxiques du peptide amyloïde Abeta dans la maladie d'Alzheimer. Vieillissement et démences Un défis médical, scientifique et socio-économique (133-137). France : Lavoisier Médecine Sciences. (Published).

Articles de journaux

  • Vanderperre B, Staskevicius AB, Tremblay G, McCoy M, O'Neill MA, Cashman NR, Roucou X. (2011). An overlapping reading frame in the PRNP gene encodes a novel polypeptide distinct from the prion protein. FASEB J. 2373-2386.

Articles de conférence

  • Marie Brunet, Vivian Delcourt, Jean-Francois Jacques, Xavier Roucou. (2017). ALS-linked FUS geneencodes for a second small protein, altFUS, that regulates FUS localization andmacro-autophagy. Gordon Research Conference: Amyotrophic Lateral Sclerosis and related neurodegenerative disorders. (Published).
  • Marie Brunet, Vivian Delcourt, Jean-Francois Jacques, Xavier Roucou. (2017). FUSDiscovery of a novel protein encoded in an alternative open reading frame (ORF) of gene and its importance in Amyotrophic Lateral Sclerosis (ALS). Keystone Symposia: Omics Strategies to Study the Proteome. (Published).
  • Marie Brunet, Vivian Delcourt, Jean-Francois Jacques, Xavier Roucou. (2017). Large-scale proteomicanalysis of alternative open reading frames reveals a new player in ALS, altFUSencoded within FUS gene. Canadian National Proteomic Network 2017 Annual Meeting. (Published).
  • Maxime Béland, Xavier Roucou. (2014). Using the prion protein against toxic species of Aß amyloid peptide in Alzheimer's disease. Aging and dementia: a medical, scientific and socio-economic challenge (Paris, France), (Published).
  • Béland M (student I supervised), Tremblay G, Roucou X. (2013). Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates. Prion 2013 (Banff, Canada), (Published).
  • Beaudoin S (supervised student), Tremblay G, Roucou X. (2012). Genetic mutants of prion protein inhibit the assembly of stress granules and P-Bodies, two RNA granules implicated in mRNA decay. Prion 2012 (Amsterdam, The Netherlands), (Published).
  • Vanderperre B (supervised student), Tremblay G, Motard J, Boisvert, FM, Roucou X. (2012). Large-scale identification of alternative open reading frames translation products expands the human proteome. Human Protein Organization 2012 (Boston, USA), (Published).
  • Vanderperre B (supervised student), Staskevicius AB, Tremblay G, McCoy M, O’Neill MA, Cashman NR, Roucou X. (2011). An overlapping reading frame in the PRNP gene encodes a novel polypeptide distinct from the prion protein. Prion 2011 (Montreal, Canada), (Published).
  • Shott R, Appanah C, Grenier C, Tremblay G, Roucou X, Schang L. (2011). Cytoplasmic PrP Dysregulates Signaling Pathways that Control Protein Synthesis and Aggresome Formation. Prion 2011 (Montreal, Canada), (Published).
  • Béland M (supervised student), Roucou X. (2011). Dimerization of PrP Induces a Signalling Cascade Responsible for the Cleavage, Secretion, and Accumulation of the Unstructured N-terminal Domain in Insoluble Extracellular Deposits. Prion 2011 (Montreal, Canada), (Published).
  • Roostaee A (supervised student), Roucou X. (2011). Prion-Like Propagation and Neurotoxicity of Recombinant α-Synuclein Aggregates Initiated by Dimerization. Prion 2011 (Montreal, Canada), (Published).
  • Vanderperre B (supervised student), Staskevicius A (supervised student), Tremblay G, Roucou X. (2010). AltPrP : a novel, stress regulated peptide encoded by Prnp. Prionet Canada (Ottawa, Canada). (Published).
  • Vanderperre B (supervised student), Staskevicius A (supervised student), Tremblay G, Roucou X. (2010). AltPrP: a novel cryptic out-of-frame polypeptide encoded by Prnp. Prion 2010 (Salzburg, Austria). (Published).
  • Béland M (supervised student), Roucou X. (2010). Dimerization of PrP induces a TACE-mediated proteolytic cleavage and release of its N-terminal domain in the extracellular space. Prionet Canada 2010 (Vancouver, Canada), (Published).
  • Beaudoin S (supervised student). (2010). Genetic prion mutants inhibit two RNA granules, P-Bodies and stress granules. Prionet Canada (Ottawa, Canada). (Published).
  • Roostaee A (supervised student), Roucou X. (2010). In vitro propagation and neurotoxicity of dimerization-induced prion aggregates. PROTEO (Montreal, Canada). (Published).
  • Vanderperre B (supervised student), Staskevicius A (supervised student), Tremblay G, Roucou X. (2010). PrP's mRNA encodes two proteins : PrP and a novel cryptic out-of-frame polypeptide termed AltPrP. Prionet Canada (Vancouver, Canada). (Published).

Propriétés intellectuelles

Patents

  • (2011). OLIGOMER-SPECIFIC AMYLOID BETA EPITOPE AND ANTIBODIES. WO2011106885 A1. Canada. (Granted/Issued).

Registered Copyrights

  • Alternative human proteins used as biomarkers and therapeutic targets. (Registered).

Autres contributions

Cours enseignés

  • Biochimie des protéines-Pathologies associées. BCH711. (2013-01-16 à 2013-04-03). Niveau : Graduate. (2CR).
  • Maladies à prions. VIM6012. (2007-12-04 à 2012-12-07). Niveau : Graduate. (3CR).
  • Prions et neuropathogenèse. MCB6045. (2007-11-08 à 2012-11-15). Niveau : Graduate. (3CR).
  • Biotechnologies de la santé. BCM504. (2006-08-03 à 2012-12-20). Niveau : Undergraduate. (3CR).
  • Structure et mécanismes des macromolécules biologiques. BCH720. (2005-09-07 à 2012-11-28). Niveau : Graduate.

Présentations

  • (2018). Back to reality: updating the coding potential of genomes and recognizing the polycistronic nature of eukaryotic genes. Recomb-CG 2018. Canada.
  • (2018). OpenProt: a more comprehensive database to explore proteomes in neurodegenerative diseases. First symposium The seven centers of Excellence in Neurodegeneration. Montpellier, France.
  • (2017). Alternative protein in neurodegenerative diseases. Cross-disease analysis of pathways in amyloid-based neurodegenerative diseases symposium. Paris, France.
  • (2016). MID51/Mief1 codes for two different proteins, both involved in mitochondrial fission. 2nd International Symposium "One mitochondrion, many diseases. Biological and molecular perspectives. Germany.
  • (2015). A new proteome expessed from neglected coding sequences. Scientific conference at Vertex Pharmaceuticals (Canada) Inc. Montreal, Canada.
  • (2015). Dual-coding genes in neurodegenerative disorders. Groupe de recherche universitaire sur le médicament and Groupe de recherche sur le système nerveux central. Montreal, Canada.
  • (2015). Mitochondrial dynamics protein of 51 kDa (MID51) and its alternative protein. 1st International Symposium "One mitochondrion, many diseases. Biological and molecular perspectives. Canada.
  • (2014). An unexplored parallel proteome expressed from "forgotten"coding sequences. Journée Phare 2014. Orford, Canada.
  • (2014). An unexplored parallel proteome expressed from "forgotten" coding sequences. Centre de recherche du CHU de Québec/Hôtel-Dieu. Québec, Canada.
  • (2014). An unexplored proteome in neurodegenerative disorders. Conférences scientifiques du centre de recherche de l'institut universitaire en santé mentale de Québec. Québec, Canada.
  • (2014). Dual coding genes in neurodegenerative disorders. Neuroscience for mental health seminars, Douglas Mental Health University Institute. Montreal, Canada.
  • (2013). Function of the alternative proteome in neurodegenerative diseases. Department of Biochemistry, University of Toronto. Toronto, Canada.
  • (2013). Function of the alternative proteome in neurodegenerative diseases. Aging and dementia, a triple medical, scientific and socio-academic challenge. National medical academy, France. Paris, France.
  • (2012). Large-scale identification of alternative open reading frames translation products expands the human proteome. Human Protein Organization 2012. Boston, United States.
  • (2012). Prnp, one gene, two proteins:PrP and Alt-PrP. PrioNet Canada. Vancouver, Canada.
  • (2011). Prion protein mutants interfere with RNA silencing. Mechanisms of Neurodegeneration Rocky Mountain Laboratories. Hamilton, United States.
  • (2011). The alternative prion protein AltPrP. Department of Medical Microbiology University of Manitoba. Winnipeg, Canada.
  • Vanderperre, B (supervised student); Staskevicius (supervised student); Tremblay, G. (2010). AltPrP: a novel cryptic out-of-frame polypeptide encoded by Prnp. Prion 2010. Salzburg, Austria.
  • (2010). A stress-induced alternative polypeptide encoded within the prion protein gene. Dept of Cell Biology University of Geneva. Geneva, Switzerland.
  • (2010). A stress-induced alternative polypeptide encoded within the prion protein gene. Prion Japan. Tokyo, Japan.
  • Staskevicius, A (supervised student). (2010). Cryptic out-of-frame initiation of human PrP mRNA produces a novel 9 kDa polypeptide. Prion Canada. Ottawa, Canada.
  • (2010). Prion protein mutants interfere with the assembly of RNA granules. Dept of Pathology and Cell Biology. Montreal, Canada.

Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.